Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Joseph M Tuscano
City of Hope Comprehensive Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
- Los Angeles General Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Keck Medical Center of Usc Pasadena
Pasadena, California, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- Smilow Cancer Center/yale-New Haven Hospital
New Haven, Connecticut, United States
- Yale University
New Haven, Connecticut, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Northside Hospital
Atlanta, Georgia, United States
- University of Kansas Clinical Research Center
Fairway, Kansas, United States
- University of Kansas Cancer Center
Kansas City, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
- University of Kentucky/markey Cancer Center
Lexington, Kentucky, United States
- Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- Wayne State University/karmanos Cancer Institute
Detroit, Michigan, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- Vanderbilt University/ingram Cancer Center
Nashville, Tennessee, United States
- Ut Southwestern/simmons Cancer Center-Dallas
Dallas, Texas, United States
- University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Nov 2016
- Primary completion
- 24 Nov 2025
- Completion
- 24 Nov 2025
- Last update posted
- 26 Nov 2025
- Registered enrollment
- 35
- Registry id
- NCT02568553
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.